Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Sangiorgio VF, Nam A, Chen Z, Orazi A, Tam W. GATA1 downregulation in prefibrotic and fibrotic stages of primary myelofibrosis and in the myelofibrotic progression of other myeloproliferative neoplasms. Leuk Res. 2021;100:106495.

Narayanan D, Pozdnyakova O, Hasserjian RP, Patel SS, Weinberg OK. Effect of DNMT3A variant allele frequency and double mutation on clinicopathologic features of patients with de novo AML. Blood Adv. 2021;5(11):2539-2549.

Restin T, Schmugge M, Cushing MM, Haas T. Comparison between intraoperative bleeding score and ROTEM® measurements to assess coagulopathy during major pediatric surgery. Transfus Apher Sci. 2021;60(5):103191.

Martini R, Chen Y, Jenkins BD, Elhussin IA, Cheng E, Hoda SA, et al. Investigation of triple-negative breast cancer risk alleles in an International African-enriched cohort. Sci Rep. 2021;11(1):9247.

Wangsiricharoen S, Wakely PE, Siddiqui MT, Ali SZ. Cytopathology of chondromyxoid fibroma: a case series and review of the literature. J Am Soc Cytopathol. 2021;10(4):366-381.

Mahdi Z, Ettel MG, Gonzalez RS, Hart J, Alpert L, Fang J, et al. Metastases can occur in cirrhotic livers with patent portal veins. Diagn Pathol. 2021;16(1):18.

Wang TZ, Simon MS, Westblade LF, Saiman L, E Furuya Y, Calfee DP. Quantitative characterization of high-touch surfaces in emergency departments and hemodialysis facilities. Infect Control Hosp Epidemiol. 2021;42(4):474-476.

Jacob RP, Flynn J, Devlin SM, Maloy M, Giralt SA, Maslak P, et al. Universal Engraftment after Allogeneic Hematopoietic Cell Transplantation Using Cryopreserved CD34-Selected Grafts. Transplant Cell Ther. 2021;27(8):697.e1-697.e5.

Manning DK, Shivdasani P, Koeller DR, Schwartz A, Rana HQ, Garber JE, et al. Assessment of genomic alterations in non-syndromic von Hippel-Lindau: Insight from integrating somatic and germline next generation sequencing genomic data. Data Brief. 2021;39:107653.

Moskowitz AJ, Ghione P, Jacobsen E, Ruan J, Schatz JH, Noor S, et al. A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas. Blood. 2021;138(26):2828-2837.